Correlation of biological cervical cancer with its demographic and obstetric parameters in Ain Defla region, Algeria

Aicha Laissaoui, Safia Houari, Mohamed Abada, Salima Ait Kaci, Farida Laissaoui

Abstract

This study aims to determine the prevalence of cervical dysplasia and its relationship to biological and demographic characteristics. A transversal observational study is based on 236 conventional smears collected in Algeria. A Pap smear was taken, fixed and then stained using Papanicolaou staining. The interpretation of the results was done using the Bethesda 2014 system. Some of the patients with abnormal smears had colposcopy and, if necessary, a biopsy. Other patients with low-grade lesions were recommended to have their smears resumed 6 months or 1 year later.  Cytological analysis was performed for 236 patients. Among those, 94 patients had abnormal smears, 45 cases with ASCUS (19.06 %), LSIL was reported in 36 cases (15.25%), AGC was observed in 6 cases (2.54 %), HSIL in 4 cases (1.69 %), only 1(0.42 %) case observed in SCC and 2 cases in ADK (0.84 %). Also, 34 low-grade patients underwent cytological examination 6 months to 1 year later to determine the persistence, regression or progression of low-grade dysplasia. During follow-up, persistence was observed in 35.29% (n= 12) of cases, progression to high-grade squamous intraepithelial lesion (HSIL) was detected in 5.88% (n= 2), while 52.88% (n= 20) of the patients experienced regression. Moreover, the frequency of Pap smear positivity correlated with the duration of OC use, the duration of marriage and parity. In this study, the prevalence of abnormal smear was 39.84 % for cytology. The colposcopy and histology confirmed just 3.33%. Meanwhile, these results highlight the importance of early screening of this pathology. (Afr J Reprod Health 2022; 26[10]: 31-37).

Full Text:

PDF

References

Diouf D, Diop G, Diarra CAT, NgomAI, Niane K, Ndiaye M, KaS, FayeO and Dem A. Systematic screening for cervical cancer in Dakar region: prevalence and correlation with biological and socio-demographic parameters. Infectious agents and cancer 2020;15(1): 1-8.

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I and Bray F. Global Cancer Observatory, corp-author. Lyon, France: International Agency for Research on Cancer; 2018. Mar 18;2019.CancerToday.

Golfetto L, Alves EV, Martins TR, Sincero TCM, Castro JBS, Dannebrock C, Oliveira JG, Levi JE, Onofre ASC and Bazzo ML. PCR-RFLP assay as an option for primary HPV test. Brazilian Journal of Medical and BiologicalResearch.2018;51:e7098.doi:10.1590/1414-431x20177098.

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX and de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of million women with normal cytological findings. The InfectiousDiseases.2010;202:1789–1799. doi:10.1086/657321.

Kocjan BJ, Bzhalava D, Forslund O, Dillner J and Poljak M. Molecular methods for identification and characterization of novel papilloma viruses .Clinical Microbiology and Infection. 2015;21:808–816. doi:10.1016/j.cmi.2015.05.011.

WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva:WHO;2013.

Catarino R, Petignat P, Dongui Gand Vassilakos P. Cervical cancer screeningin developing countries at a crossroad: Emerging technologies and policy choices. World journal of clinical oncology. 2015;6: 281.

Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin‐Hirsch PP, Mustafa R A, Schünemann H, Paraskevaidis E and Arbyn M. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database of Systematic Reviews; 2017: (8).

Fields MM. New cervical cancer screening guidelines: Was the annual pap too much of a good thing, Advanced Practice Providers in Oncology. 2013; 4:59–64.

Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J Garcia F A R, Moriarty A, Waxman A,Wilbur D, Wentzensen N, Downs L , Spitzer M, Moscicki A B, Franco E L,Stoler M H ,Schiffman M ,Castle P E and Myers E R. American Cancer Society, American Society for Colposcopy and Cervical Pathology and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Cancer Journal for Clinicians.2012;62:147–72.

The Union for International Cancer Control (UICC) Geneva:Union for International Cancer Control;2017. 2017GLOBOCAN annual report.

Devesa SS, Young JL, Jr, Brinton LA and Fraumeni JF., Jr Recent trends in cervixutericancer. Cancer.1989; 64:2184–90.

Pretorius R, Semrad N, Watring W and Fotheringham N. Presentation of cervical cancer. Gynecologic Oncology. 1991;42:48–53.

Lee HK, Kim SN, Khang SK, Kang CS and Yoon HK. Quality control program and its results of Korean Society for Cytopathologists. Korean Journal ofPathology.2008; 19:65–71.

Nayar R andWilbur DC.The pap test and Bethesda 2014.Cancercytopathology2015;123, 271–281.

Sachan PL, Singh M, Patel M L and Sachan R. A study on cervical cancer screening using pap smear test and clinical correlation. Asia-Pacific journal of oncology nursing 2018: 5(3), 337.

National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. Journal of the American Medical Association.1989; 262:931–34.

Solomon D, Davey DD, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S ,Sherman M , Wilbur D , Wright Jr T and Young N . The 2001 Bethesda System Terminology for reporting result of cervical cytology. Journal of the American Medical Association. 2002;287:2114–19.

Boumansour NFZ, Tenni A, Damouche AI and Nori M. Epidemiological profile of cervical cancer in Oran, Algeria,2014–2015.Revue d'Épidémiologie et de Santé Publique 2018; 66:S288-S289.

Wang Z, Wang J, Fan J, Zhao W, Yang X, Wu L, Li D Ding L, Wang W, Xu J, Stram M, Zhao CH and Hao M, Risk factors for cervical intraepithelial neoplasia and cervical cancer in Chinese women: large study in Jiexiu, Shanxi province, China. Journal of Cancer 2017 ;8: 924.

El-Moselhy EA, Salim SA, Hagrass SA. Prevalence and Risk Factors of Cervical Intraepithelial Neoplasia and Cervical Cancer among Ever Married Adult Females in Egypt: A Survey Study. J Compr Cancer Res. 2017;1(1):1- 5.

Eluf- Neto J, Booth M, Munoz N, Bosch FX, Meijer CJ and Walboomers JM.Human papillomavirus and invasive cervical cancer in Brazil. British Journal of Cancer. 1994;69:114–119.

Munoz N, Franceschi S, Bosetti C, MorenoV, Herrero R, Smith JS, Shah KV, Meijer CJ and Bosch FX, International Agency for Research on Cancer Multicentric Cervical Cancer Study GRole of parity and human papillomavirus in cervical cancer: the IARC multicentric case–control study.Lancet.2002;359:1093–1101.

Parazzini F, Chatenoud L, La Vecchia C, Negri E, Franceschi S and Bolis G. Determinants of risk of invasive cervical cancer in young women. British Journal of Cancer. 1998;77:838–841.

Brinton LA, Hamman RF, Huggins GR, Lehman HF, Levine RS, Mallin K and Fraumeni JF., Jr Sexual and reproductive risk factors for invasive squamous cell cervical cancer. Journal of the National Cancer Institute.1987a;79:23–30.

Oh HY, Kim MK, Seo SS and Lee JK.,. Association of combined tobacco smoking and oral contraceptive use with cervical intraepithelial neoplasia 2 or 3 in Korean women. Journal of epidemiology 2016;26: 22–29.

Loopik DL, Int Hout J, Melchers WJ, Massuger LF, Bekkers RL and Siebers AG. Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade iii or worse: a population-based study.European Journal of Cancer 2020;124:102–109.

Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ and Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. American Journal of Obstetrics and Gynecology.2007;197:340–5.

Refbacks

  • There are currently no refbacks.